We applaud the FDA’s clearance for Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test another important milestone that has the potential to advance the Alzheimer’s diagnostic process and bring more accessible, scalable tools to physicians and specialists, ultimately benefitting people living with Alzheimer’s disease. Developed as a collaboration between Eli Lilly & Co and Roche, Elecsys® […]
The landscape of Alzheimer’s diagnostics is undergoing a significant transformation. Recent clinical studies and reports from mid-2026 confirm the increasing reliability of blood biomarkers in identifying Alzheimer-related pathologies. These blood tests enable a more precise and earlier diagnosis compared to traditional methods, suggesting that blood tests could play a central role in clinical routines and […]
The Global Alzheimer’s Platform Foundation enrolled 1,000+ participants with unprecedented 27% from traditionally understudied populations Washington D.C., August 11, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) has reached full enrollment for the innovative Bio-Hermes-002 Study, successfully recruiting more than 1,000 participants. The milestone marks an important step toward advancing the next generation of blood and digital biomarker […]
The cancellation of ongoing NIH-funded Alzheimer’s research grants is a serious setback in the fight against Alzheimer’s disease. Halting peer-reviewed studies wastes taxpayer investments, disrupts years of scientific progress, and delays the discoveries that millions of patients and families urgently need. Alzheimer’s disease is one of our nation’s greatest public health challenges. Progress depends on […]
August 3, 2026Author(s)Yogesh Shah, MD, MPH, FAAFP Dr. Yogesh Shah, MD, reviews the evidence supporting P-tau217 as a reliable rule-in biomarker for Alzheimer’s pathology and discusses how clinicians can incorporate blood-based testing into patient evaluation.As blood-based biomarkers move closer to routine clinical use, demonstrating agreement with established diagnostic standards remains essential. For Alzheimer disease (AD), […]
Residents of the College Park Towers Senior Apartments in Orlando gathered Wednesday for Bilingual Activ8 Your Brain Bingo, an event designed to promote brain health through fun, interactive activities. The nonprofit Global Alzheimer’s Platform Foundation partnered with Conquest Research to offer brain health education and free cognitive screenings. Engage speaks with participants and organizers about simple habits that can help […]
24 Jul 2026 Part 2 of 2No, they are not Optimus Jr, Megatron’s clones, or any other new, amyloid-shattering members of the Tron family franchise of transformer robots, though perhaps Roche does not mind if you think so for a moment. Rather, the TRONTIER twins are currently enrolling Phase 3 trials for early AD, and […]
Across three independent studies, the NeuLogiq® Platform two-minute tablet-based Symbol Swap task delivered clinically meaningful discrimination between control, MCI and Alzheimer’s dementia groups and detected blood-biomarker-defined pathology — including in clinically normal individuals — with accuracy matching or exceeding the ADAS-Cog, MoCA and MMSE benchmarks. LONDON, July 15, 2026 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global […]
Symbol Swap matched or exceeded ADAS-Cog, MoCA, and MMSE across three independent studiesBy Henry BakerPublished: Jul 15 2026, 3:39 PM EDT On the final day of the world’s largest dementia research conference, a startup presented data Wednesday suggesting that a two-minute tablet task can do what a trained clinician typically takes 10 to 45 minutes to […]
July 1, 2026 The Nguoit Viet News wrote an article in Vietnamese on how hundreds of residents attended a free health fair at St. Columban Church. The Mobile Research Unit was at the event and had a record of 55 screenings while sharing the importance of brain health. To read the article in Vietnamese from […]
GAP Experts Share Poster Presentations at Alzheimer’s Association International Conference (AAIC) Washington D.C., July 9, 2026- The Global Alzheimer’s Platform Foundation®, (GAP) will have two poster presentations at the 2026 Alzheimer’s Association International Conference (AAIC) being held in Londong July 12 through July 15. All posters are in the Exhibit Hall in Excel London, Royal Victoria Dock, 1 […]
Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias Washington D.C., July 8, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Taudia to the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of […]
By:Ingrid Johansen, Date: July 7, 2026 A significant global research initiative is underway to develop a convenient blood test for diagnosing Alzheimer’s disease. The study focuses on three specific proteins linked to the condition, aiming to compare the efficacy of the test with current brain scans. If successful, this new test could offer a simpler […]
Washington D.C., July 1, 2026- Elevance Health, formerly Anthem Inc., updated their medical policy, to allow for blood-based biomarker testing for the detection and diagnosis of Alzheimer’s disease, making Elevance Health one of the first major payors to outline coverage criteria. GAP President John Dwyer said, “GAP applauds the decision by Elevance Health to explicitly endorse […]
John Dwyer, the President of the Global Alzheimer’s Platform Foundation (GAP) joins TrialSiteNews to discuss a collaboration and partnership with Circular Genomics. The partnership will analyze blood test samples to investigate the potential for circular RNA biomarkers to assist in the diagnosis & treatment of Alzheimer’s Disease. Topics covered: Press Release: https://globalalzplatform.org/2026/05…
Story by Amy Scherzer, Bay Correspondent Tearful yet joyful, the annual Inspire, Imagine & Hope Gala honored Tampa neurologist Dr. Susan Steen for her 40-plus years advancing brain health education and leading clinical trials for Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. Gala co-chairs Lyle Fogarty and Dr. Shannon Moroney shared the personal impact of […]
Free Memory Screenings Offered Across the Country during Alzheimer’s and Brain Awareness Month WASHINGTON, DC (June 4, 2026)- Alzheimer’s research sites across the country are recognizing Alzheimer’s and Brain Awareness Month by offering free memory screenings for adults age 55 and older. Throughout June, researchers are raising awareness about brain health and the importance of learning about […]
Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data Washington D.C., May 28, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Circular Genomics, a biotechnology company revolutionizing neurological and psychiatric precision medicine, access to analyze Bio-Hermes-001 samples to investigate the potential for circular RNA […]
Free Memory Screenings Offered to Promote Importance of Brain Health WASHINGTON, DC (May. 20, 2026)- Alzheimer’s research sites across the country are honoring National Clinical Trials Day by offering free memory screening for adults age 55 and older. National Clinical Trials Day recognizes the progress made in developing treatments and therapies, advances which could not have been […]
TrialSite Staff | Making Biomedical Research Evidence Accessible to All May. 18, 2026, 2:30 p.m. The global battle against Alzheimer’s disease may increasingly hinge on one critical factor: detecting the disease earlier, faster, and more accurately before irreversible neurological decline takes hold. This week, the Global Alzheimer’s Platform Foundation (GAP) announced the continued expansion of its Bio-Hermes-002 […]
The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of dementia… The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of […]
Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias. Washington D.C., May 18, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce the continued expansion of the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of cognitive conditions, alongside MRI and PET imaging and diverse […]
Could Alzheimer’s disease one day be detected with a simple blood test instead of expensive brain scans? In this episode of the TrialSite News Farago Podcast, we speak with John Dwyer, President and CEO of the Global Alzheimer’s Platform Foundation (GAP), about the Bio-Hermes-002 study and the future of Alzheimer’s detection. The conversation explores how […]
Representatives from Butler Hospital’s Memory and Aging Program and the Global Alzheimer’s Platform recently visited the Swansea Council on Aging to discuss normal memory changes with age and new research in Alzheimer’s prevention. The session also encouraged residents to engage with the Acti-v8 initiative and join a prevention registry. This content is adapted from materials provided by Swansea Council On Aging This article includes […]